Grant of Warrants
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
9 June 2023
Cellular Goods PLC
("Cellular Goods" or "the Company")
Grant of Warrants
Cellular Goods (LSE: CBX) a UK-based skincare and wellness company providing premium consumer products formulated with lab-produced cannabinoids, announces that it has granted a total of 3,000,000 warrants to subscribe for new ordinary shares of £0.001 each ("Warrants") to members of its Advisory Board. The Warrants are exercisable at 1.5 pence per ordinary share.
One third of the warrants will vest on 8 June 2024 with the remaining two thirds vesting in 24 equal monthly instalments thereafter. The Warrants have an exercise period from the date of grant to 8 June 2028.
Following the issue of the Warrants, the Company has a total of 12,500,000 warrants in issue.
For further information please contact:
Chairman and interim CEO
via Tancredi +44 207 887 7633
+44 787 645 5323
First Sentinel Corporate Finance
Corporate Broker & Advisor
+44 7876 888 011
+44 207 399 9427
Tancredi Intelligent Communication
+44 744 922 6720
+44 789 755 7112
About Cellular Goods PLC:
Cellular Goods develops and markets premium quality skincare and wellness products based on proprietary formulations incorporating biosynthetic lab-made cannabinoids. Our branded products are efficacy-led and research-backed and available online in the UK and US. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com.